Study Protocol for Better Evidence for Selecting Transplant Fluids (BEST-Fluids): a pragmatic, registry-based, multi-center, double-blind, randomized controlled trial evaluating the effect of intravenous fluid therapy with Plasma-Lyte 148 versus 0.9%

ANZDATA

Article

Posted25 May 2020
PMID32450917

AuthorsMichael G. Collins, Fahim, M, Pascoe, E, Dansie, K, Philip A. Clayton, Howard, K, Johnson, D, McArthur, C, Rachael C. McConnochie, Peter F. Mount, Reidlinge, D, Robison, L, Varghese, J, Vergara, L, Weinberg, L, BEST-Fluids Investigators; Australasian Kidney Trials Network

Periodical/sTrials

Study Protocol for Better Evidence for Selecting Transplant Fluids (BEST-Fluids): a pragmatic, registry-based, multi-center, double-blind, randomized controlled trial evaluating the effect of intravenous fluid therapy with Plasma-Lyte 148 versus 0.9%

Kidney replacement therapy within 12 months of childbirth in Australia

Frequency of therapy alerts during the first 30 days of automated peritoneal dialysis and its relationship to time on treatment

A feasibility study for understanding the demand and acceptability of a systematic symptom monitoring process in end-stage kidney disease

Estimating a Minimal Important Difference for the EQ-5D-5L Utility Index in Dialysis Patients

Study Protocol for Better Evidence for Selecting Transplant Fluids (BEST-Fluids): a pragmatic, registry-based, multi-center, double-blind, randomized controlled trial evaluating the effect of intravenous fluid therapy with Plasma-Lyte 148 versus 0.9%

Explore more

Kidney replacement therapy within 12 months of childbirth in Australia

Frequency of therapy alerts during the first 30 days of automated peritoneal dialysis and its relationship to time on treatment

A feasibility study for understanding the demand and acceptability of a systematic symptom monitoring process in end-stage kidney disease

Estimating a Minimal Important Difference for the EQ-5D-5L Utility Index in Dialysis Patients